April 25, 2016
1 min read

Ilizarov treatment provided satisfactory foot, ankle function in children

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Through successful Ilizarov treatment, children with atrophic-type congenital pseudarthrosis of the tibia can obtain satisfactory foot and ankle function at maturity, according to results.

Researchers compared 24 patients who underwent Ilizarov treatment for unilateral atrophic-type congenital pseudarthrosis of the tibia to a control group of 24 participants. Researchers assessed all patients with validated outcome questionnaires, radiographs, physical examination, instrumented motion analysis, including a multisegmental foot model, and pedobarographic measurement.


Sang Gyo Seo

Results showed a mean score on the AOFAS ankle-hindfoot scale of 89.9 and a mean score on the Oxford Ankle Foot Questionnaire of 42.8 among patients with congenital pseudarthrosis of the tibia. Through motion analysis and pedobarographic measurement, researchers found a slower walking speed due to the short stride length, decreased dorsiflexion in hallux motion, increased hindfoot pronation in the presence of forefoot supination, diminished ankle push-off power, delayed time to heel-rise and decreased forefoot pressure relative to hindfoot pressure on the side affected by congenital pseudarthrosis of the tibia. However, results showed the affected side had a relatively well-preserved sagittal motion of the hindfoot and forefoot. According to results of a subgroup analysis, the tibiofibular synostosis group and the intact-fibula group had no significant differences in terms of clinical outcome scores and most biomechanical parameters. – by Casey Tingle


Disclosures: Seo reports no relevant financial disclosures. Please see the full study for a list of all other authors’ relevant financial disclosures.